ScreenerHero

CRDL Cardiol Therapeutics Inc.

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · cardiolrx.com
1.320USD+0.76%Mkt Cap: 160.40M $P/E: —

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx,…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$66.23BUSDP/E 25.7
TAK
Takeda Pharmaceutical Company Limited
$58.68BUSD
TEVA
Teva Pharmaceutical Industries Limited
$45.70BUSDP/E 65.3
GALD
Galderma Group AG
$43.27BUSDP/E 56.1
HLN
Haleon plc
$39.67BUSDP/E 18.4
SDZ
Sandoz Group AG
$34.93BUSDP/E 60.5
HLN
Haleon plc
$32.73BUSDP/E 19.0
ZOE
Zoetis Inc.
$28.56BUSDP/E 12.2
ZTS
Zoetis Inc.
$29.57BUSDP/E 11.8
UTHR
United Therapeutics Corporation
$23.38BUSDP/E 19.5
VTRS
Viatris Inc.
$20.09BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.43BUSDP/E 112.9
NBIX
Neurocrine Biosciences, Inc.
$14.58BUSDP/E 21.0
IPN
Ipsen S.A.
$12.99BUSDP/E 23.5
ELAN
Elanco Animal Health Incorporated
$11.17BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.22BUSDP/E 27.9
KRK
Krka, d. d.
$8.66BUSDP/E 19.3
ALKS
Alkermes plc
$6.95BUSDP/E 109.1
HIMS
Hims & Hers Health, Inc.
$6.89BUSD
AMRX
Amneal Pharmaceuticals, Inc.
$6.84BUSDP/E 40.1

Key Statistics

Company
Market Cap160.40M USD
Enterprise Value127.06M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-33.82M USD
Revenue/Share—
Last Price1.320 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees18
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.72
PEG—
EV/EBITDA-3.54
EV/Revenue—
P/S—
P/B8.86
EPS (TTM)-0.25
EPS (Forward)-0.23
52W Range
0.880030% of range2.340
52W High2.340 USD
52W Low0.8800 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-189.17%
ROA-143.18%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-23.85M USD
CapEx (TTM)24.48K USD
FCF Margin—
FCF Yield-9.65%
Net Debt-25.97M USD
Net Debt/EBITDA0.72
Balance Sheet
Debt/Equity0.01
Current Ratio5.55
Quick Ratio5.01
Book Value/Sh0.15 USD
Cash/Share0.22 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)8.383 USD
Upside (mean)+535.1%
Target Range4.973 USD – 10.74 USD
4.973+535.1% to mean10.74
# Analysts5
Ownership
Shares Out.121.51M
Float91.98M
Insiders2.27%
Institutions26.40%
Short Interest
Short Ratio2.0d
Short % Float2.82%
Short % Out.2.75%
Shares Short3.31M
Short (prev mo.)2.31M
Technical
SMA 501.742 (-24.2%)
SMA 2001.286 (+2.7%)
Beta0.72
S&P 52W Chg16.45%
Avg Vol (30d)1.71M
Avg Vol (10d)1.52M
Technical Indicators
RSI (14)27.4
MACD-0.1172
MACD Signal-0.0427
MACD Hist.-0.0745
BB Upper2.312 USD
BB Middle1.756 USD
BB Lower1.200 USD
BB Width63.31%
ATR (14)0.1251 USD
Vol Ratio (20d)2.39x